texas oncology more breakthroughs. more victories

Share:

 
 

Austin Midtown Research & Clinical Trials

Austin Midtown participates in a wide range of groundbreaking research that is paving the way for new breakthroughs in cancer care. As a Texas Oncology patient, you may be able to take part in these innovative clinical trials.

Texas Oncology-Austin Midtown

Biliary Cancer

STAR Infigratinib vs Gem/Cis Cholangio

A Phase 3 Multicenter, Open-Label, Randomized, Controlled Study of Oral Infigratinib versus Gemcitabine with Cisplatin in Subjects with Advanced/Metastatic or Inoperable Cholangiocarcinoma with FGFR2 Gene Fusions/Translocations: The PROOF Trial (QBGJ398-301) Read More

Phase: III

Bladder Cancer

Ph1/2 AMG510 KRAS mut G12C Solid Tumors

A Phase 1/2, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 510 Monotherapy in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation and AMG 510 Combination Therapy in Subjects With Advanced NSCLC With KRAS p.G12C Mutation (CodeBreak 100) (20170543) Read More

Phase: II

Sitravatinib + Nivo Adv/Met Urothelial

A Phase 2 Study of Sitravatinib in Combination with Nivolumab in Patients With Advanced or Metastatic Urothelial Carcinoma (516-003) Read More

Phase: II

NeoAdj Chemo +/- Nivo/IDO1inh MIBC

A Phase 3, Randomized, Study of Neoadjuvant Chemotherapy alone versus Neoadjuvant Chemotherapy plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Post-Surgery Therapy with Nivolumab or Nivolumab and BMS-986205 in Participants with Muscle-Invasive Bladder Cancer (CA017078) Read More

Phase: III

STAR Ph2 enfortumab (ASG-22CE)Urothelial

A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001 Read More

Phase: II

Brain Cancer

A Phase 3, Randomized, Open-Label Study To Evaluate the Efficacy and Safety of Eflornithine with Lomustine Compared to Lomustine Alone in Patients with Anaplastic Astrocytoma That Progress/Recur After Irradiation and Adjuvant Temozolomide Chemotherapy (STELLAR study)

Phase: III

Breast Cancer

TALAZ IN GERMLINE BRCA1/2 MUT BC

(C3441020) A PHASE 2, NON-RANDOMIZED, OPEN LABEL, SINGLE ARM, MULTI-CENTER STUDY OF TALAZOPARIB FOR NEOADJUVANT TREATMENT OF GERMLINE BRCA1/2 MUTATION PATIENTS WITH EARLY HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 NEGATIVE BREAST CANCER Read More

Phase: II

CONTESSA2: Ph2 HER2- HR+ BC

A Multinational, Multicenter, Phase 2 Study of Tesetaxel plus a Reduced Dose of Capecitabine in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Who Have Not Previously Received a Taxane(ODO-TE-B201) Read More

Phase: II

Phase 1/2a BMS-986253 + Nivo

A Phase 1/2a Study of BMS-986253 in Combination with Nivolumab in Advanced Cancers (CA027002) Read More

Phase: I/II

Ph3 Pembro HR+/HER2- BC

A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK3475-KN756) Read More

Phase: III

CheckMate 848: Ph2 Nivo+Ipi Solid tumors

CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H) Read More

Phase: II

Ph 3 Tuca/Placbo + T-DM1 HER2+

STAR: Randomized, double-blind, phase 3 study of tucatinib or placebo in combination with ado-trastuzumab emtansine (T-DM1) for subjects with unresectable locally-advanced or metastatic HER2+ breast cancer (SGNTUC-016) Read More

Phase: III

Cervical Cancer

CheckMate 848: Ph2 Nivo+Ipi Solid tumors

CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H) Read More

Phase: II

Colon Cancer

Ph1/2 AMG510 KRAS mut G12C Solid Tumors

A Phase 1/2, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 510 Monotherapy in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation and AMG 510 Combination Therapy in Subjects With Advanced NSCLC With KRAS p.G12C Mutation (CodeBreak 100) (20170543) Read More

Phase: II

Phase 1/2a BMS-986253 + Nivo

A Phase 1/2a Study of BMS-986253 in Combination with Nivolumab in Advanced Cancers (CA027002) Read More

Phase: I/II

CheckMate 848: Ph2 Nivo+Ipi Solid tumors

CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H) Read More

Phase: II

Endometrial Cancer

Ph1/2 AMG510 KRAS mut G12C Solid Tumors

A Phase 1/2, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 510 Monotherapy in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation and AMG 510 Combination Therapy in Subjects With Advanced NSCLC With KRAS p.G12C Mutation (CodeBreak 100) (20170543) Read More

Phase: II

Epithelial Carcinomas

Phase 1a/2a Dose Escalation Trial to Determine Safety, Tolerance, MTD, and Preliminary Antineoplastic Activity of AVID100, in Patients With Advanced or Metastatic Solid Tumors of Epithelial Origin

Esophageal Cancer

CheckMate 848: Ph2 Nivo+Ipi Solid tumors

CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H) Read More

Phase: II

Gastric Cancer

CheckMate 848: Ph2 Nivo+Ipi Solid tumors

CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H) Read More

Phase: II

Head and Neck Cancer

Phase 1/2a BMS-986253 + Nivo

A Phase 1/2a Study of BMS-986253 in Combination with Nivolumab in Advanced Cancers (CA027002) Read More

Phase: I/II

Ph1b/2 Copanlisib+Nivo Solid Tumors

An open-label, multi-center, phase 1b/2 study to evaluate thesafety and efficacy of copanlisib in combination with nivolumabin patients with advanced solid tumors (19769) Read More

Phase: I/II

CheckMate 848: Ph2 Nivo+Ipi Solid tumors

CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H) Read More

Phase: II

Leukemia

Ublituximab+TGR-1202 Cross-over

(UTX-TGR-204) A Multi-Center, Open-Label, Compassionate Use Extension Study of Ublituximab (TG-1101) in Combination with Umbralisib (TGR-1202) for Patients Previously Enrolled in Protocol UTX-TGR-304 Read More

Phase: II

Ph 1/2 PIM kinase Adv Malignancies

A Phase 1/2 Study of INCB053914 in Subjects With Advanced Malignancies (INCB 53914-101) Read More

Phase: I

Ph3b 1L CLL debulk combo

A phase 3b study in previously untreated Chronic Lymphocytic Leukemia (CLL) subjects, excluding those with the 17p deletion, to evaluate debulking regimens prior to initiating venetoclax combination therapy (M16-788) Read More

Phase: III

Ph3b Venetoclax AML

A Phase 3b, Single-Arm, Multicenter Open-Label Study of Venetoclax in Combination with Azacitidine or Decitabine in an Outpatient Setting in AML Patients Ineligible for Intensive Chemotherapy (M19-072) Read More

Phase: III

Liver Cancer

Ph1/2 AGEN1884 Adv Refractory cancer

A Phase 1/2, Open-Label, Multicenter Study to Evaluate the Safety, Pharmacokinetics, andPharmacodynamics of an Anti¨CCTLA-4 Human Monoclonal Antibody (AGEN1884)in Subjects with Advanced or Refractory Cancer and in Subjects who have Progressed During Treatment with a PD-1/PD-L1 Inhibitor as their Most Recent Therapy (C-500-01) Read More

Phase: I/II

Ph1b/2 Copanlisib+Nivo Solid Tumors

An open-label, multi-center, phase 1b/2 study to evaluate thesafety and efficacy of copanlisib in combination with nivolumabin patients with advanced solid tumors (19769) Read More

Phase: I/II

CheckMate 848: Ph2 Nivo+Ipi Solid tumors

CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H) Read More

Phase: II

Lung Cancer

Ph 1/1b Immunotherapy Combo in NSCLC

(AB928CSP0004) A Phase 1/1b Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants with Lung Cancer Read More

Phase: I

Ph 3 Sit+Nivo vs. Docetaxel NSCLC

516-005: A Randomized Phase 3 Study of Sitravatinib in Combination with Nivolumab Versus Docetaxel in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer with Disease Progression On or After Platinum-Based Chemotherapy in Combination with Checkpoint Inhibitor Therapy - SAPPHIRE Study Read More

Phase: III

Ph2 MGCDs+Nivo NSCLC

A Parallel Phase 2 Study of Glesatinib, Sitravatinib or Mocetinostat in Combination With Nivolumab in Advanced or Metastatic Non-Small Cell Lung Cancer (MRTX-500) Read More

Phase: II

Ph1/2 AMG510 KRAS mut G12C Solid Tumors

A Phase 1/2, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 510 Monotherapy in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation and AMG 510 Combination Therapy in Subjects With Advanced NSCLC With KRAS p.G12C Mutation (CodeBreak 100) (20170543) Read More

Phase: II

Phase 1/2a BMS-986253 + Nivo

A Phase 1/2a Study of BMS-986253 in Combination with Nivolumab in Advanced Cancers (CA027002) Read More

Phase: I/II

Ph 1b FIH XMT-1536 Solid Tumor NaPi2b

A Phase 1b, First-in-Human, Dose Escalation and Expansion Study of XMT-1536 In Patients with Solid Tumors Likely to Express NaPi2b (MER-XMT-1536-1) Read More

Phase: I

Tepotinib stage IIIB/IV NSCLC w/ METex14

A Phase II single-arm trial to investigate tepotinib inadvanced (Stage IIIB/IV) non-small cell lung cancerwith MET exon 14 (METex14) skipping alterations or MET amplification (VISION): MS200095-0022 Read More

Phase: II

Ph3 neoadj Atezo NSCLC

A Phase III, Double-Blinded, Multicenter, Randomized Study Evaluating The Efficacy and Safety of Neo-adjuvant Treatment with Atezolizumab or Placebo in Combination with Platinum-Based Chemotherapy in Patients with Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer (GO40241) Read More

Phase: III

STAR Ph3 Peme+PltChem+/-Pemb NSCLC TKI

A Randomized, Double-Blind, Phase 3 Study of Pemetrexed + PlatinumChemotherapy with or without Pembrolizumab (MK-3475) in TKI-resistant EGFR-mutated Tumors in Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) Participants (KEYNOTE-789; MK-3475-789) Read More

Phase: III

Ph1b/2 Copanlisib+Nivo Solid Tumors

An open-label, multi-center, phase 1b/2 study to evaluate thesafety and efficacy of copanlisib in combination with nivolumabin patients with advanced solid tumors (19769) Read More

Phase: I/II

STAR Ph3 ALK+ mNSCLC (Brigatinib-3001)

Brigatinib-3001- A Phase 3 Randomized Open-label Study of Brigatinib (ALUNBRIG®)Versus Alectinib (ALECENSA®) in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer Patients Who Have Progressed on Crizotinib (XALKORI®) Read More

Phase: III

Ph 1 PF-06821497 R/R SCLC, CRPC & FL

C2321001: A PHASE I DOSE ESCALATION AND EXPANDED COHORT STUDY OF PF-06821497 IN THE TREATMENT OF ADULT PATIENTS WITH RELAPSED/REFRACTORY SMALL CELL LUNG CANCER (SCLC), CASTRATION RESISTANT PROSTATE CANCER (CRPC) AND FOLLICULAR LYMPHOMA (FL) Read More

Phase: I

CheckMate 848: Ph2 Nivo+Ipi Solid tumors

CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H) Read More

Phase: II

Lymphomas

PhIV Gazyva, Adv FL

(MO40597) A MULTICENTRIC, OPEN-LABEL, SINGLE ARM STUDY OF OBINUTUZUMAB SHORT DURATION INFUSION (SDI) IN PATIENTS WITH PREVIOUSLY UNTREATED ADVANCED FOLLICULAR LYMPHOMA (PHASE IV STUDY) Read More

Phase: IV

STAR BV in older pts w/1L cHL or PTCL

(SGN35-015) A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) and CD30-expressing peripheral T-cell lymphoma (PTCL) in older patients or patients with significant comorbidities ineligible for standard chemotherapy Read More

Phase: II

Ph2 R/R MCL (CITADEL-205)

A Phase 2, Open-Label, 2-Cohort, Multicenter Study of INCB050465, a PI3Kä Inhibitor, in Relapsed or Refractory Mantle Cell Lymphoma Previously Treated With or Without a BTK Inhibitor (CITADEL-205)- INCB050465-205 Read More

Phase: II

TGR-1202 +/- Ublituximab in NHL

A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR-1202 with or without Bendamustine and TGR-1202 alone in Patients with Previously Treated Non-Hodgkin''s Lymphoma (UTX-TGR-205) Read More

Phase: II

Ph 1 PF-06821497 R/R SCLC, CRPC & FL

C2321001: A PHASE I DOSE ESCALATION AND EXPANDED COHORT STUDY OF PF-06821497 IN THE TREATMENT OF ADULT PATIENTS WITH RELAPSED/REFRACTORY SMALL CELL LUNG CANCER (SCLC), CASTRATION RESISTANT PROSTATE CANCER (CRPC) AND FOLLICULAR LYMPHOMA (FL) Read More

Phase: I

Ph1 INCB050465 B-Cell (CITADEL-112)

INCB 50465-112: A Phase 1, Open-Label, Dose-Finding Study of INCB050465 in Combination With Investigator Choice of Rituximab, Bendamustine and Rituximab, or Ibrutinib in Participants With Previously Treated B-Cell Lymphoma (CITADEL-112) Read More

Phase: I

Melanoma

Phase 1/2a BMS-986253 + Nivo

A Phase 1/2a Study of BMS-986253 in Combination with Nivolumab in Advanced Cancers (CA027002) Read More

Phase: I/II

Myelodysplastic Syndrome

Ph 1/2 PIM kinase Adv Malignancies

A Phase 1/2 Study of INCB053914 in Subjects With Advanced Malignancies (INCB 53914-101) Read More

Phase: I

Myelofibrosis

Ph 1/2 PIM kinase Adv Malignancies

A Phase 1/2 Study of INCB053914 in Subjects With Advanced Malignancies (INCB 53914-101) Read More

Phase: I

STAR Ph2 Itacitinib +/- Ruxo in MF

INCB 39110-209, An Open-Label Phase 2 Study of Itacitinib (INCB039110) in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis Read More

Phase: II

Myelomas

Ph1 SEA-BCMA R/R MM

A phase 1 study of SEA-BCMA in patients with relapsed or refractory multiple myeloma (SGNBCMA-001) Read More

Phase: I

Ph 1/2 PIM kinase Adv Malignancies

A Phase 1/2 Study of INCB053914 in Subjects With Advanced Malignancies (INCB 53914-101) Read More

Phase: I

Ph1/2 INCB001158 + SC Dara vs Dara SC MM

A Randomized Open-Label Phase 1/2 Study of INCB001158Combined With Subcutaneous (SC) Daratumumab, Compared toDaratumumab SC, in Participants With Relapsed or RefractoryMultiple Myeloma (INCB 01158-206) Read More

Phase: I/II

Ovarian Cancer

Ph 1b FIH XMT-1536 Solid Tumor NaPi2b

A Phase 1b, First-in-Human, Dose Escalation and Expansion Study of XMT-1536 In Patients with Solid Tumors Likely to Express NaPi2b (MER-XMT-1536-1) Read More

Phase: I

CheckMate 848: Ph2 Nivo+Ipi Solid tumors

CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H) Read More

Phase: II

Pancreatic Cancer

Ph1/2 AMG510 KRAS mut G12C Solid Tumors

A Phase 1/2, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 510 Monotherapy in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation and AMG 510 Combination Therapy in Subjects With Advanced NSCLC With KRAS p.G12C Mutation (CodeBreak 100) (20170543) Read More

Phase: II

Phase 1/2a BMS-986253 + Nivo

A Phase 1/2a Study of BMS-986253 in Combination with Nivolumab in Advanced Cancers (CA027002) Read More

Phase: I/II

CheckMate 848: Ph2 Nivo+Ipi Solid tumors

CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H) Read More

Phase: II

Prostate Cancer

Ph 2 Nivo+Ipil, Ipil mono or Caba CR mPC

A Phase 2 Trial of Nivolumab Plus Ipilimumab, Ipilimumab Alone, or Cabazitaxel in Men with Metastatic Castration-Resistant Prostate Cancer (CA209-650) Read More

Phase: II

STAR Abirat+pred +/- abemaciclib mCRPC

A Phase 2, Randomized, Double-blind, Placebo-Controlled Study of Abiraterone Acetate Plus Prednisone with or without Abemaciclib in Patients with Metastatic Castration-Resistant Prostate Cancer (I3Y-MC-JPCM) Read More

Phase: II

Biomarker DNA Defect Men Prostate

Biomarker Study to Determine Frequency of DNA-repair Defects in Men with Metastatic Prostate Cancer (64091742PCR0002) Read More

Ph 1 PF-06821497 R/R SCLC, CRPC & FL

C2321001: A PHASE I DOSE ESCALATION AND EXPANDED COHORT STUDY OF PF-06821497 IN THE TREATMENT OF ADULT PATIENTS WITH RELAPSED/REFRACTORY SMALL CELL LUNG CANCER (SCLC), CASTRATION RESISTANT PROSTATE CANCER (CRPC) AND FOLLICULAR LYMPHOMA (FL) Read More

Phase: I

CheckMate 848: Ph2 Nivo+Ipi Solid tumors

CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H) Read More

Phase: II

STAR Rucaparib v PhysC mCRPC (TRITON3)

TRITON3: A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician''s Choice of Therapy for Patients withMetastatic Castration-resistant Prostate Cancer Associated withHomologous Recombination Deficiency (CO-338-063) Read More

Phase: III

Renal Cancer

Phase 1/2a BMS-986253 + Nivo

A Phase 1/2a Study of BMS-986253 in Combination with Nivolumab in Advanced Cancers (CA027002) Read More

Phase: I/II

Skin Cancer

Phase 1/2a BMS-986253 + Nivo

A Phase 1/2a Study of BMS-986253 in Combination with Nivolumab in Advanced Cancers (CA027002) Read More

Phase: I/II

Solid Tumors

STAR Ph2 Pemigatinib Solids FGFR

(INCB 54828-207) A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207) Read More

Phase: II

Ph1/2 FIH BMS-986249 + Nivo Solid Tumor

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors Read More

Phase: I

Ph1/2 AMG510 KRAS mut G12C Solid Tumors

A Phase 1/2, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 510 Monotherapy in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation and AMG 510 Combination Therapy in Subjects With Advanced NSCLC With KRAS p.G12C Mutation (CodeBreak 100) (20170543) Read More

Phase: II

Phase 1/2a BMS-986253 + Nivo

A Phase 1/2a Study of BMS-986253 in Combination with Nivolumab in Advanced Cancers (CA027002) Read More

Phase: I/II

Ph1b/2 Copanlisib+Nivo Solid Tumors

An open-label, multi-center, phase 1b/2 study to evaluate thesafety and efficacy of copanlisib in combination with nivolumabin patients with advanced solid tumors (19769) Read More

Phase: I/II

Ph 1 PF-06821497 R/R SCLC, CRPC & FL

C2321001: A PHASE I DOSE ESCALATION AND EXPANDED COHORT STUDY OF PF-06821497 IN THE TREATMENT OF ADULT PATIENTS WITH RELAPSED/REFRACTORY SMALL CELL LUNG CANCER (SCLC), CASTRATION RESISTANT PROSTATE CANCER (CRPC) AND FOLLICULAR LYMPHOMA (FL) Read More

Phase: I

CheckMate 848: Ph2 Nivo+Ipi Solid tumors

CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H) Read More

Phase: II

Testicular Cancer

CheckMate 848: Ph2 Nivo+Ipi Solid tumors

CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H) Read More

Phase: II

Thyroid Cancer

CheckMate 848: Ph2 Nivo+Ipi Solid tumors

CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H) Read More

Phase: II

Urothelial Cancer

STAR Ph3 FGFR erdafitinib urothelial

(42756493BLC3001) A Phase 3 Study of Erdafitinib Compared with Vinflunine or Docetaxel or Pembrolizumab in Subjects with Advanced Urothelial Cancer and Selected FGFR Gene Aberrations (THOR) Read More

Phase: III

Phase 1/2a BMS-986253 + Nivo

A Phase 1/2a Study of BMS-986253 in Combination with Nivolumab in Advanced Cancers (CA027002) Read More

Phase: I/II

Phase 1/2a BMS-986253 + Nivo

A Phase 1/2a Study of BMS-986253 in Combination with Nivolumab in Advanced Cancers (CA027002) Read More

Phase: I/II

Sitravatinib + Nivo Adv/Met Urothelial

A Phase 2 Study of Sitravatinib in Combination with Nivolumab in Patients With Advanced or Metastatic Urothelial Carcinoma (516-003) Read More

Phase: II

Sitravatinib + Nivo Adv/Met Urothelial

A Phase 2 Study of Sitravatinib in Combination with Nivolumab in Patients With Advanced or Metastatic Urothelial Carcinoma (516-003) Read More

Phase: II

STAR Ph2 enfortumab (ASG-22CE)Urothelial

A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001 Read More

Phase: II

CheckMate 848: Ph2 Nivo+Ipi Solid tumors

CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H) Read More

Phase: II

Uterine Cancer

CheckMate 848: Ph2 Nivo+Ipi Solid tumors

CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H) Read More

Phase: II

CheckMate 848: Ph2 Nivo+Ipi Solid tumors

CA209848 - A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H) Read More

Phase: II